Authors: Jastreboff AM, Kaplan LM, Frías JP, et al.
-24.2% mean body weight reduction at 48 weeks with 12 mg dose
In this phase 2, double-blind, randomized, placebo-controlled trial, 338 adults with obesity or overweight were assigned to receive once-weekly subcutaneous retatrutide (1 mg, 4 mg, 8 mg, or 12 mg) or placebo for 48 weeks. Dose escalation followed predefined schedules. At 48 weeks, the least-squares mean percentage change in body weight with retatrutide reached up to -24.2% in the 12-mg group, accompanied by substantial improvements in cardiometabolic parameters.
Landmark phase 2 trial published in the New England Journal of Medicine demonstrating unprecedented weight reduction of up to 24.2% over 48 weeks with the GIP/GLP-1/Glucagon triple agonist retatrutide.
* Educational commentary prepared by Peptide Health Digest editors to provide context on study methodology.
Jastreboff AM, Kaplan LM, Frías JP, et al.
This study record was compiled from public biomedical repositories for educational and informational reference. Peptide Health Digest does not claim authorship of the original investigation.
